Unfortunately, therapeutic targeting of this pathway in AML using Magrolimab, a CD47 blocking antibody that inhibits this reaction, has yielded disappointing results in clinical trials, resulting in termination of some of the studies [2, 3]. The gene discussed is CD47; the disease is acute myeloid leukemia.